TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02647255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Description: PE treatment\>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone pulse
Description: methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse
Description: methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
Study: NCT03466749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Eluting Balloon Catheter
Description: Paclitaxel Eluting Balloon Catheter
Study: NCT00618709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: ATX-101 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: ATX-101 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: ATX-101 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: ATX-101 single dose
Study: NCT00328094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous intravenous insulin infusion
Description: Tight glucose control versus standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous intravenous insulin infusion
Description: Tight glucose control versus standard of care
Study: NCT00533052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective and Cognitive Skills Training
Description: 24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
Study: NCT04361214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.
Study: NCT02631902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Community-based exercise program with 3 weekly exercise sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Community-based exercise program with 3 weekly exercise sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Community-based dietary intervention program
Study: NCT02778841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
Study: NCT02710916

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SD-OCT Spectralis
Description: All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SD-OCT Spectralis
Description: All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SD-OCT Spectralis
Description: All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
Study: NCT04047849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics, oral Azithromycin and oral Amoxicillin
Description: Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
Study: NCT04233671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based relapse prevention and peer mentoring
Description: Importantly, the treatment will utilize a group format. Group process can serve as a vital agent in breaking down client denial about drug abuse problems. Groups have also been shown to be suitable for treating problems commonly associated with substance abuse, including depression, isolation, and shame.~Additionally, groups intrinsically have many rewarding benefits, including reducing isolation and enabling members to witness the recovery of others. The eight-week group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, then followed by group sessions led by peer mentors for an additional four weeks.
Study: NCT04460534

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diagnostic
Description: The principle of this study is to propose to patients in whom a COVID-19 infection is suspected and who are screened for the disease, the joint search for the virus in the semen.
Study: NCT04819412

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ROTAVAC®
Description: ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC 5C -F1
Description: ROTAVAC 5C formulation BBIL-R2014-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC 5C -F2
Description: ROTAVAC 5C formulation BBIL-R2014-2
Study: NCT04484155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Micro Sclerostomy (MIMS)
Description: The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
Study: NCT04422314

Intervention type: DIAGNOSTIC_TEST
Intervention: T-Detect Lyme
Description: T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: T-Detect Lyme
Description: T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: T-Detect Lyme
Description: T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: T-Detect Lyme
Description: T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: T-Detect Lyme
Description: T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.
Study: NCT05083052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis 15%
Description: oothpaste formulation with 15% propolis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis 10%
Description: Toothpaste formulation with 10% propolis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation of toothpaste without active ingredient.
Study: NCT04632056

Intervention type: DRUG
Intervention: Beovu
Description: There is no treatment allocation. Patients administered Beovu by prescription that have started before inclusion of the patient into the study were enrolled.
Study: NCT04018807

Intervention type: OTHER
Group type: OTHER
Intervention: Resource pamphlet
Description: The pamphlet will list violence prevention, mental health, and substance abuse services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Therapy
Description: Remote therapy sessions will include mindfulness exercises and motivational interviewing techniques.
Study: NCT04746261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIP + treatment as usual
Description: ASSIP:~First session: Videotaped narrative interview focusing on the background to the suicidal crisis.~Second session: Video playback. The patient and the therapist watch the recorded interview together, stopping the film regularly to add information. The patient is given a psychoeducational text to read and comment on as homework.~Third session: Compilation of a written case formulation of the individual's vulnerability and triggering events that preceded the suicidal crisis. Individual preventive measures are developed by the patient and the therapist together and written down in a document that the patient keeps and which is attached to the patient's medical record.~Fourth session (optional): Mini-exposure.~Standardized letters: The therapist contacts the patient by letter during two years, every three months the first year and every six months the second year.~Treatment as usual: As described bellow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual and patient safety
Description: All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records.
Study: NCT03328845

Intervention type: DRUG
Group type: OTHER
Intervention: NovoRapid
Description: Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl

Intervention type: DRUG
Group type: OTHER
Intervention: NovoRapid
Description: Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
Study: NCT04746261

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual and patient safety
Description: All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records.
Study: NCT02093403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03945994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connecting People Intervention
Description: Improve the resourcefulness of social networks of people with mental health problems
Study: NCT03734900

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: 5ml Placebo infusion of 0.9% Sodium Chloride

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: Device: Aeon Acti-PRP~5ml autologous platelet rich plasma injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PL injection
Description: Device: Aeon Acti-PRP~5ml autologous platelet lysate injection
Study: NCT03871959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEBIO1143
Description: 3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
Study: NCT04128488

Intervention type: OTHER
Intervention: Abdominal MR Imaging
Description: Imaging to evaluate visceral adipose tissue and hepatic lipid content

Intervention type: OTHER
Intervention: Abdominal MR Imaging
Description: Imaging to evaluate visceral adipose tissue and hepatic lipid content

Intervention type: OTHER
Intervention: Cardiac MRI/MRS
Description: Imaging to evaluate cardiac function and structure

Intervention type: OTHER
Intervention: Cardiac MRI/MRS
Description: Imaging to evaluate cardiac function and structure

Intervention type: OTHER
Intervention: Oral Glucose Tolerance Testing
Description: Blood testing to evaluate changes in glucose and insulin in response to oral glucose load

Intervention type: OTHER
Intervention: Oral Glucose Tolerance Testing
Description: Blood testing to evaluate changes in glucose and insulin in response to oral glucose load

Intervention type: OTHER
Intervention: Whole Body, Lumbar Spine, and Hip DEXA Imaging
Description: Imaging to evaluate fat and lean body mass as well as bone mineral density

Intervention type: OTHER
Intervention: Whole Body, Lumbar Spine, and Hip DEXA Imaging
Description: Imaging to evaluate fat and lean body mass as well as bone mineral density
Study: NCT03004924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP640
Description: Instill 1 drop of SHP640 (povidone-iodine \[PVPI\] 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PVP-I 0.6%
Description: Instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
Study: NCT01325194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine
Description: 50 mg intrathecally three times
Study: NCT02982044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suprasystolic (300 mmHg) cuff compressions
Description: 10 minutes of ECG-gated repeated suprasystolic (300 mmHg) cuff compressions, with inflation occurring every other heart cycle. These cuff compressions may be triggered 0 seconds, 0.2 seconds, or 0.4 seconds from the R spike (systole) on the ECG signal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip exercise
Description: 10 minutes of ECG-gated rhythmic handgrip exercise at 30% maximal voluntary contraction, with contraction occurring every other heart cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive heat stress
Description: 10 minutes of passive heat stress at 42 degrees Celsius with a commercially available heating blanket
Study: NCT01010399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosamprenavir/ritonavir
Description: Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
Study: NCT02798120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Open label, topical SB204 4%
Study: NCT00463840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX 6
Description: this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
Study: NCT01048970

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Assessment
Description: Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA-DHA arm
Description: Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
Study: NCT00232466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Procedure:~The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay.
Study: NCT06241066

Intervention type: OTHER
Intervention: no-Intervention
Description: no-Intervention

Intervention type: OTHER
Intervention: no-Intervention
Description: no-Intervention

Intervention type: OTHER
Intervention: no-Intervention
Description: no-Intervention

Intervention type: OTHER
Intervention: no-Intervention
Description: no-Intervention
Study: NCT00625404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
Study: NCT03317457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab and Tremelimumab
Description: immun checkpoint inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Anthracycline
Study: NCT04369235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tCES
Description: The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. tCES will be applied for 20 minutes at an intensity of 1.0 -1.5 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tCES
Description: The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham tCES will consist of a 5-second ramp up to 1.0-1.5 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
Study: NCT03796715

Intervention type: DIAGNOSTIC_TEST
Intervention: Red Cell Distribution Width (RDW)
Description: A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.

Intervention type: DIAGNOSTIC_TEST
Intervention: Presepsin (sCD14-ST)
Description: : A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.
Study: NCT03328845

Intervention type: DRUG
Group type: OTHER
Intervention: Apidra
Description: Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl

Intervention type: DRUG
Group type: OTHER
Intervention: Apidra
Description: Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
Study: NCT04332679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group A - control group
Description: 20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B - Test group
Description: 20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
Study: NCT00286962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIP 2007C implantable insulin pump
Description: Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous subcutaneous insulin infusion (CSII) or MDI
Study: NCT03758794

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interactive lecture
Description: an interactive lecture will be given to a group of dental interns students on child abuse recognition and reporting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: online education
Description: an online educational module will be sent to a group of dental interns students on child abuse recognition and reporting
Study: NCT04233983

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Endometriosis Surgery
Description: Patient with ERROR(endometrioma related reduction in ovarian reserve), and endometrioma larger than 3 cm diameter will be operated after IVF\&ICSI procedure. Operation will be done by senior surgeons of our department. Laparoscopic endometrioma operation procedure consists of excision of endometrioma cyst with its capsule from ovary without using any electric modality to prevent ovarian damage.
Study: NCT03146325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE
Description: A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MATCHING PLACEBO
Description: TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
Study: NCT03402321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin Sponge Sheet
Description: sheets act as a mechanical barrier used to protect the denuded area of the palatal donor site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvogyl
Description: paste form with analgesic action to protect the palatal donor site and help to relief pain